Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Leishmaniasis is a vector-borne disease caused by obligate, intracellular protozoa of the
genus Leishmania and transmitted by phlebotomine sandflies. It is found mostly in tropical
and subtropical areas then it has spread into southern Europe. Increased international travel
and immigration have led to an increased diagnosis of leishmaniasis cases in nonendemic areas
(Kollipara et al., 2016). Foci of CL, caused by L. ma¬jor, occur in Afghanistan, Egypt, Iran,
Iraq, Jordan, Libya, Morocco, Palestine, Pakistan, Saudi Arabia, Sudan, Syria, Tunisia, and
Yemen. Many researchers have studied leishmaniasis in the endemic northern African countries,
e.g., Morocco, Algeria, Tunisia, Egypt, and Libya. One of the established endemic
leishmaniasis Libyan provinces is Al-jabal Al-gharbi province, where CL comprises a major
parasitic health problem (Abdellatif et al., 2013).To evaluate the efficacy of intralesional
cryotherapy, intralesional Voriconazole, and oral doxycycline in the treatment of cutaneous
leishmaniasis compared to the conventional treatment (intralesional SSG).